去勢抗性攝護腺癌患者接受歐洲紫杉醇治療之臨床結果
王賢祥、歐宴泉、程千里、賀昊中、裘坤元、陳卷書、
李建儀、楊晨洸、陳正哲、林嘉彥
臺中榮民總醫院外科部泌尿外科
Clinical outcomes in castration resistant prostate cancer patients treated with docetaxel
Shian-Shiang Wang, Yen-Chuan Ou, Chen-Li Cheng, Hao-Chung Ho, Kun-Yuan Chiu, Chuan-Shu Chen, Jian-Ri Li, Cheng-Kuang Yang, Cheng-Che Chen, Chia-Yen Lin
Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taiwan,
Purpose: Weevaluated the clinical outcomes of castration resistant prostate cancer (CRPC) patients treated with Docetaxel in Taichung Veterans General Hospital.
Materials and Methods:From Dec 2004 to Feb 2015, 208 patients with castration resistant prostate cancer were treated with Docetaxel70-75mg/m2, IV, every three to four weeks or 50mg/m2, every two weeks. The PSA response,time to progression duration, overall survival and adverse events wereanalyzed.
Results:The median age of the 208 patients was 69 years (range 44-86) and the median PSA when started Docetaxelwas 47 ng/ml (range 2.24-4761). The median treatment courses of the patients were 6 (range 1-44). PSA response was found in 105patients (50.5%). Twenty-eight patients (13.5%) had the phenomenon of PSA flare up. The median progression free survival was 5 months(range0-54) and the median overall survival was 13 months (range 0-80). The most common subjective adverse effects were neutropenia. About one-third patients (35%) had grade3-4 neutropenia
Conclusions:Good PSA response and fair survival outcome were demonstrated in CRPC patients treated with docetaxel. However, high risk of neutropenia should be kept in mind.